307 related articles for article (PubMed ID: 21865609)
1. Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck.
Hoellein A; Pickhard A; von Keitz F; Schoeffmann S; Piontek G; Rudelius M; Baumgart A; Wagenpfeil S; Peschel C; Dechow T; Bier H; Keller U
Oncotarget; 2011 Aug; 2(8):599-609. PubMed ID: 21865609
[TBL] [Abstract][Full Text] [Related]
2. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
Machiels JP; Schmitz S
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy.
Bedi A; Chang X; Noonan K; Pham V; Bedi R; Fertig EJ; Considine M; Califano JA; Borrello I; Chung CH; Sidransky D; Ravi R
Mol Cancer Ther; 2012 Nov; 11(11):2429-39. PubMed ID: 22927667
[TBL] [Abstract][Full Text] [Related]
4. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
[TBL] [Abstract][Full Text] [Related]
5. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
[TBL] [Abstract][Full Text] [Related]
6. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
7. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Agulnik M
Med Oncol; 2012 Dec; 29(4):2481-91. PubMed ID: 22252310
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
[TBL] [Abstract][Full Text] [Related]
9. Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer.
Bhola NE; Freilino ML; Joyce SC; Sen M; Thomas SM; Sahu A; Cassell A; Chen CS; Grandis JR
Mol Cancer Ther; 2012 Jun; 11(6):1236-46. PubMed ID: 22491800
[TBL] [Abstract][Full Text] [Related]
10. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
11. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
Iida M; Bahrar H; Brand TM; Pearson HE; Coan JP; Orbuch RA; Flanigan BG; Swick AD; Prabakaran PJ; Lantto J; Horak ID; Kragh M; Salgia R; Kimple RJ; Wheeler DL
Mol Cancer Ther; 2016 Sep; 15(9):2175-86. PubMed ID: 27422810
[TBL] [Abstract][Full Text] [Related]
12. Does dexamethasone inhibit anticancer activity of cetuximab in squamous cell carcinoma cell lines of the head and neck?
Wagenblast J; Baghi M; Mörtel S; Hirth D; Thron L; Arnoldner C; Gstöttner W; May A; Hambek M
Oncol Rep; 2009 Jul; 22(1):171-6. PubMed ID: 19513520
[TBL] [Abstract][Full Text] [Related]
13. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
[TBL] [Abstract][Full Text] [Related]
14. Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade.
Boyko-Fabian M; Niehr F; Distel L; Budach V; Tinhofer I
PLoS One; 2014; 9(6):e98867. PubMed ID: 24927258
[TBL] [Abstract][Full Text] [Related]
15. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
16. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
[TBL] [Abstract][Full Text] [Related]
17. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Zibelman M; Mehra R
Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma.
Li C; Iida M; Dunn EF; Wheeler DL
Radiother Oncol; 2010 Nov; 97(2):330-7. PubMed ID: 20667610
[TBL] [Abstract][Full Text] [Related]
19. The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism.
Pickhard A; Siegl M; Baumann A; Huhn M; Wirth M; Reiter R; Rudelius M; Piontek G; Brockhoff G
Oncotarget; 2014 Jul; 5(14):5428-38. PubMed ID: 24980817
[TBL] [Abstract][Full Text] [Related]
20. EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.
Mehra R; Cohen RB; Harari PM
Curr Oncol Rep; 2008 Mar; 10(2):176-84. PubMed ID: 18377832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
